Workflow
Nektar(NKTR)
icon
Search documents
Nektar(NKTR) - 2019 Q3 - Quarterly Report
2019-11-07 00:43
PART I: FINANCIAL INFORMATION [Item 1. Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) Nektar Therapeutics reported a **$327.2 million net loss** for the nine months ended September 30, 2019, primarily due to the absence of **$1.06 billion in 2018 BMS collaboration revenue** [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | September 30, 2019 | December 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $81,224 | $194,905 | | Total current assets | $1,578,824 | $1,437,687 | | Total assets | $2,088,294 | $2,150,172 | | **Liabilities & Equity** | | | | Total current liabilities | $125,350 | $82,002 | | Total liabilities | $599,583 | $432,597 | | Total stockholders' equity | $1,488,711 | $1,717,575 | - Total assets decreased slightly, while total liabilities increased primarily due to the recognition of **$134.9 million** in operating lease right-of-use assets and corresponding liabilities of **$154.4 million** following the adoption of new lease accounting standards (ASC 842)[13](index=13&type=chunk)[43](index=43&type=chunk) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Statements of Operations Summary (in thousands, except per share data) | Metric | Q3 2019 | Q3 2018 | Nine Months 2019 | Nine Months 2018 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $29,218 | $27,762 | $80,755 | $1,153,497 | | R&D Expense | $99,048 | $102,895 | $324,197 | $290,653 | | G&A Expense | $23,983 | $18,718 | $71,570 | $57,666 | | Net Income (Loss) | $(98,808) | $(96,143) | $(327,229) | $779,525 | | Diluted EPS | $(0.56) | $(0.56) | $(1.87) | $4.34 | - The significant decrease in revenue and shift from net income to net loss for the nine-month period is primarily due to the recognition of **$1.06 billion** from the BMS collaboration agreement in 2018, which was not repeated in 2019[16](index=16&type=chunk)[83](index=83&type=chunk)[95](index=95&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary for Nine Months Ended September 30 (in thousands) | Cash Flow Category | 2019 | 2018 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $(203,458) | $835,764 | | Net cash provided by (used in) investing activities | $71,405 | $(1,467,476) | | Net cash provided by financing activities | $18,449 | $849,298 | | **Net (decrease) increase in cash and cash equivalents** | **$(113,681)** | **$217,499** | - The shift from positive to negative cash flow from operations was mainly due to the absence of the large upfront payment from BMS received in 2018. Financing activities in 2018 were significantly higher due to the **$790.2 million** issuance of common stock to BMS[23](index=23&type=chunk)[167](index=167&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's financial position, key collaboration agreements, adoption of new lease accounting standards, and ongoing legal proceedings - The company's research and development pipeline focuses on treatments for cancer, autoimmune disease, and chronic pain, financed primarily through licensing and collaboration agreements[25](index=25&type=chunk)[26](index=26&type=chunk) - On January 1, 2019, the company adopted lease accounting standard ASC 842, recording right-of-use assets of **$83.5 million** and lease liabilities of **$96.2 million**[38](index=38&type=chunk)[43](index=43&type=chunk) - The company is involved in a putative securities class action complaint and shareholder derivative complaints alleging misrepresentations about the efficacy and safety of its drug candidate NKTR-214[78](index=78&type=chunk) - Key collaboration agreements include a strategic partnership with BMS for NKTR-214, which provided a **$1.0 billion** upfront payment in 2018, and a co-development agreement with Eli Lilly for NKTR-358[88](index=88&type=chunk)[91](index=91&type=chunk)[96](index=96&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses pipeline advancement, attributing significant revenue decline to the absence of 2018 BMS revenue, and confirms sufficient liquidity [Overview](index=26&type=section&id=Overview) - The company's strategic focus is on its R&D pipeline, including treatments for cancer (bempegaldesleukin/NKTR-214), autoimmune disease (NKTR-358), and chronic pain (NKTR-181)[120](index=120&type=chunk) - The FDA granted Breakthrough Therapy designation for NKTR-214 in combination with Opdivo® for untreated unresectable or metastatic melanoma[121](index=121&type=chunk) - Under the BMS collaboration, Nektar shares **65%** of global profits/losses for NKTR-214 and development costs are shared (e.g., Nektar pays **32.5%** for NKTR-214 + Opdivo® combination studies), with Nektar's share capped at **$125 million** annually[89](index=89&type=chunk)[121](index=121&type=chunk) - An NDA for the chronic pain drug NKTR-181 was submitted, but the FDA missed its PDUFA target date and postponed the advisory committee meeting[126](index=126&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Revenue Breakdown (in thousands) | Revenue Source | Nine Months 2019 | Nine Months 2018 | % Change | | :--- | :--- | :--- | :--- | | Product sales | $14,302 | $16,414 | (13)% | | Royalty revenue | $29,008 | $29,898 | (3)% | | Non-cash royalty revenue | $27,585 | $24,337 | 13% | | License, collaboration and other | $9,860 | $1,082,848 | (99)% | | **Total revenue** | **$80,755** | **$1,153,497** | **(93)%** | - The **99%** decrease in License, collaboration, and other revenue for the nine months ended Sep 30, 2019, is primarily due to the recognition of **$1.06 billion** from the BMS Collaboration Agreement in the same period of 2018[139](index=139&type=chunk) - Research and development expense for the nine months ended Sep 30, 2019 increased by **12%** to **$324.2 million**, driven by clinical development of NKTR-214, NKTR-358, and NKTR-262. This increase was partially offset by **$81.4 million** in net cost reimbursements from BMS[145](index=145&type=chunk)[146](index=146&type=chunk)[147](index=147&type=chunk) - General and administrative expense increased **24%** to **$71.6 million** for the nine-month period, primarily due to costs for NKTR-181 and NKTR-214 commercialization readiness activities[150](index=150&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) - As of September 30, 2019, the company had approximately **$1.7 billion** in cash and investments and **$250.0 million** in senior secured notes due October 2020[161](index=161&type=chunk) - Management estimates that current working capital is sufficient to fund business plans for at least the next twelve months[162](index=162&type=chunk) - Net cash used in operating activities was **$203.5 million** for the first nine months of 2019, compared to net cash provided by operating activities of **$835.8 million** in the same period of 2018, with the difference largely due to the **$1.85 billion** received from BMS in April 2018[166](index=166&type=chunk)[167](index=167&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risks as of September 30, 2019, have not materially changed from the prior fiscal year-end disclosures - There were no material changes to the company's market risks since the end of the previous fiscal year[175](index=175&type=chunk) [Item 4. Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2019, with no material changes to internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of September 30, 2019[177](index=177&type=chunk) - No material changes to internal control over financial reporting were identified during the third quarter of 2019[178](index=178&type=chunk) PART II: OTHER INFORMATION [Item 1. Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in securities class action and shareholder derivative complaints alleging misrepresentations about NKTR-214, with no accrual recorded due to unestimable outcomes - The company and certain executives are named in a putative securities class action complaint and shareholder derivative actions alleging misrepresentations about the efficacy, safety, and manufacturing of NKTR-214, which allegedly inflated the stock price[78](index=78&type=chunk)[182](index=182&type=chunk) - The company states it cannot reasonably estimate any range of potential future charges and has not recorded any contingent liability for these legal proceedings[78](index=78&type=chunk) [Item 1A. Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including dependency on NKTR-214's success, clinical trial failures, manufacturing challenges, regulatory approval uncertainties, reliance on partners, capital requirements, competition, and ongoing litigation - The company is highly dependent on the success of its lead immuno-oncology candidate, NKTR-214, and any clinical or regulatory failure would significantly harm the business[184](index=184&type=chunk) - There are substantial risks and uncertainties regarding the FDA approval and commercial potential of the chronic pain drug candidate, NKTR-181, especially given the postponed advisory committee meeting[200](index=200&type=chunk)[201](index=201&type=chunk) - The company relies on contract manufacturing organizations and single-source suppliers for critical raw materials, posing risks of production delays and supply shortages[193](index=193&type=chunk)[195](index=195&type=chunk) - The company faces substantial future capital requirements and may need to raise additional capital, which could be dilutive to existing stockholders[210](index=210&type=chunk)[211](index=211&type=chunk) - Ongoing legal proceedings, including securities class action lawsuits related to NKTR-214 disclosures, pose a risk of substantial litigation costs and liabilities[236](index=236&type=chunk)[256](index=256&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=55&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities or stock repurchases were reported during the three months ended September 30, 2019 - No unregistered sales of equity securities or stock repurchases were conducted in Q3 2019[265](index=265&type=chunk) [Item 3. Defaults Upon Senior Securities](index=55&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported during the period - None reported[266](index=266&type=chunk) [Item 4. Mine Safety Disclosures](index=55&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[267](index=267&type=chunk) [Item 5. Other Information](index=55&type=section&id=Item%205.%20Other%20Information) No other information was reported for this item - None reported[268](index=268&type=chunk) [Item 6. Exhibits](index=56&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the Quarterly Report on Form 10-Q, including officer certifications and XBRL data files - Lists exhibits filed with the report, including officer certifications (31.1, 31.2, 32.1) and XBRL data files[271](index=271&type=chunk)
Nektar(NKTR) - 2019 Q2 - Earnings Call Transcript
2019-08-09 03:30
Nektar Therapeutics (NASDAQ:NKTR) Q2 2019 Earnings Conference Call August 8, 2019 5:00 PM ET Company Participants Jennifer Ruddock ??? Head of Investor Relations Howard Robin ??? President and CEO Gil Labrucherie ??? Chief Financial Officer Stephen Doberstein ??? Head of R&D Jonathan Zalevsky ??? Chief Scientific Officer Mary Tagliaferri ??? Chief Medical officer Conference Call Participants Chris Shibutani ??? Cowen Jessica Fye ??? JPMorgan Tyler Van Buren ??? Piper Jaffray Paul Choi ??? Goldman Sachs Alex ...
Nektar(NKTR) - 2019 Q2 - Quarterly Report
2019-08-09 00:26
[PART I: FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%3A%20FINANCIAL%20INFORMATION) This section provides an overview of the company's financial performance, position, and management's analysis for the reported period [Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited financial statements, highlighting a significant revenue decrease and shift to net loss primarily due to a non-recurring prior-year payment [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section details the company's financial position, including assets, liabilities, and equity at specific reporting dates Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2019 | December 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $85,424 | $194,905 | | Total current assets | $1,596,817 | $1,437,687 | | Total assets | $2,099,653 | $2,150,172 | | **Liabilities & Equity** | | | | Total current liabilities | $113,370 | $82,002 | | Total liabilities | $542,498 | $432,597 | | Total stockholders' equity | $1,557,155 | $1,717,575 | | Total liabilities and stockholders' equity | $2,099,653 | $2,150,172 | - Total assets slightly decreased from **$2.15 billion** at year-end 2018 to **$2.10 billion** at June 30, 2019[12](index=12&type=chunk) - Total stockholders' equity decreased from **$1.72 billion** to **$1.56 billion** over the same period, primarily due to the net loss incurred during the first half of 2019[12](index=12&type=chunk) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This section outlines the company's revenues, expenses, and net income or loss over specific reporting periods Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $23,315 | $1,087,717 | $51,537 | $1,125,735 | | Research and development | $106,686 | $88,334 | $225,149 | $187,758 | | Income (loss) from operations | ($110,970) | $973,600 | ($231,657) | $886,861 | | Net income (loss) | ($109,909) | $971,460 | ($228,421) | $875,668 | | Diluted EPS | ($0.63) | $5.33 | ($1.31) | $4.91 | - Total revenue for the three and six months ended June 30, 2019, decreased by **98%** and **95%** respectively, compared to the same periods in 2018, primarily due to the recognition of **$1.06 billion** in license and collaboration revenue from the BMS agreement in Q2 2018[15](index=15&type=chunk)[141](index=141&type=chunk) - The company reported a net loss of **$109.9 million** for Q2 2019, a stark contrast to the net income of **$971.5 million** in Q2 2018, reflecting the impact of the non-recurring BMS revenue[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section presents the cash inflows and outflows from operating, investing, and financing activities Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2019 | 2018 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | ($134,817) | $907,176 | | Net cash provided by (used in) investing activities | $13,152 | ($846,205) | | Net cash provided by financing activities | $12,200 | $845,439 | | Net increase (decrease) in cash and cash equivalents | ($109,481) | $906,363 | - Net cash used in operating activities was **$134.8 million** for the first six months of 2019, compared to net cash provided by operating activities of **$907.2 million** in the same period of 2018, with the 2018 figure primarily driven by upfront payments from BMS[22](index=22&type=chunk)[165](index=165&type=chunk) - Financing activities in 2018 included **$790.2 million** from the issuance of common stock to BMS, which did not recur in 2019[22](index=22&type=chunk)[168](index=168&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes provide detailed disclosures on accounting policies, significant agreements, and legal matters impacting the financial statements - The company adopted the new lease accounting standard ASC 842 on January 1, 2019, resulting in the recognition of **$83.5 million** in right-of-use assets and **$96.2 million** in lease liabilities on the balance sheet[38](index=38&type=chunk)[39](index=39&type=chunk) - A securities class action complaint was filed against the company and certain executives in October 2018, alleging misrepresentations about the efficacy and safety of NKTR-214, with no estimable potential loss or accrual recorded[80](index=80&type=chunk) - The collaboration with BMS for NKTR-214, effective April 2018, included a **$1.0 billion** upfront payment and an **$850.0 million** equity investment, with Nektar eligible for up to **$1.4 billion** in milestones and sharing profits/losses (65% Nektar / 35% BMS)[90](index=90&type=chunk)[92](index=92&type=chunk) - The collaboration with Eli Lilly for NKTR-358 included a **$150.0 million** upfront payment in 2017, with Nektar eligible for up to **$250.0 million** in additional development milestones and sharing Phase 2 development costs (25% Nektar / 75% Lilly)[97](index=97&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's strategic focus on key pipeline assets, explaining the financial performance drivers and liquidity position [Overview](index=24&type=section&id=Overview) This section outlines the company's strategic priorities and key drug development programs - The company's strategic focus is on advancing its pipeline of new investigational drugs for cancer (bempegaldesleukin/NKTR-214), autoimmune disease (NKTR-358), and chronic pain (NKTR-181)[119](index=119&type=chunk) - A broad clinical development program for NKTR-214 is being executed in collaboration with BMS, with shared development costs capped at **$125 million** annually for Nektar[120](index=120&type=chunk) - An NDA for NKTR-181 was filed with a PDUFA target action date of August 29, 2019, though a postponed advisory committee meeting may delay the decision[126](index=126&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) This section analyzes the company's revenue and operating expenses, explaining period-over-period changes Revenue Breakdown - Six Months Ended June 30 (in thousands) | Revenue Source | 2019 | 2018 | % Change | | :--- | :--- | :--- | :--- | | Product sales | $8,744 | $12,158 | (28)% | | Royalty revenue | $18,733 | $19,639 | (5)% | | Non-cash royalty revenue | $17,321 | $15,965 | 8% | | License, collaboration and other | $6,739 | $1,077,973 | (99)% | | **Total revenue** | **$51,537** | **$1,125,735** | **(95)%** | Operating Expenses - Six Months Ended June 30 (in thousands) | Expense Category | 2019 | 2018 | % Change | | :--- | :--- | :--- | :--- | | Cost of goods sold | $10,458 | $12,168 | (14)% | | Research and development | $225,149 | $187,758 | 20% | | General and administrative | $47,587 | $38,948 | 22% | - The **99%** decrease in License, collaboration and other revenue for the six months ended June 30, 2019, is primarily due to the recognition of **$1.06 billion** from the BMS Collaboration Agreement in 2018[141](index=141&type=chunk) - Research and development expense increased by **20%** for the first half of 2019 compared to 2018, driven by clinical development of NKTR-214, NKTR-358, and NKTR-262, and preclinical activities for NKTR-255[148](index=148&type=chunk)[149](index=149&type=chunk) [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, debt, and ability to fund its operations and business plans - As of June 30, 2019, the company had approximately **$1.8 billion** in cash and investments in marketable securities[133](index=133&type=chunk)[159](index=159&type=chunk) - The company has outstanding debt of **$250.0 million** in principal of senior secured notes due in October 2020[133](index=133&type=chunk)[159](index=159&type=chunk) - Management estimates that current working capital is sufficient to fund business plans for at least the next twelve months[133](index=133&type=chunk)[160](index=160&type=chunk) - Cash used in operating activities for the first six months of 2019 was **$134.8 million**, a significant shift from the **$907.2 million** cash provided by operations in the same period of 2018, which included the BMS upfront payment[164](index=164&type=chunk)[165](index=165&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section addresses the company's exposure to market risks, such as interest rate and foreign currency fluctuations - There were no material changes to the company's market risks at June 30, 2019, compared to those reported at the end of fiscal year 2018[173](index=173&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) This section reports on the effectiveness of the company's disclosure controls and internal control over financial reporting - Based on an evaluation as of June 30, 2019, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[175](index=175&type=chunk) - No material changes to the company's internal control over financial reporting were identified during the three months ended June 30, 2019[176](index=176&type=chunk) [PART II: OTHER INFORMATION](index=36&type=section&id=PART%20II%3A%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity security sales, and other miscellaneous disclosures [Legal Proceedings](index=36&type=section&id=Item%201.%20Legal%20Proceedings) This section details ongoing legal actions, including securities class action and shareholder derivative complaints, alleging misrepresentations about a key drug candidate - The company and certain executives were named in a putative securities class action complaint and shareholder derivative complaints concerning alleged misrepresentations about the efficacy and safety of NKTR-214[80](index=80&type=chunk)[180](index=180&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks, primarily focusing on drug development success, regulatory approvals, manufacturing, competition, and reliance on collaborations - The company's future success is highly dependent on the successful development, regulatory approval, and commercialization of its lead immuno-oncology candidate, NKTR-214[182](index=182&type=chunk) - Drug development is identified as a long, inherently uncertain process with a high risk of failure at every stage, where clinical study delays are common and can jeopardize commercialization[183](index=183&type=chunk)[187](index=187&type=chunk) - The NDA for NKTR-181 is subject to substantial uncertainty, including evolving FDA standards for approving new opioids and the potential for a delayed PDUFA decision[198](index=198&type=chunk) - The company relies on contract manufacturers and single-source suppliers for critical materials, where any failure or interruption could delay clinical studies and harm the business[191](index=191&type=chunk)[193](index=193&type=chunk) - The company's results depend significantly on the ability of its collaboration partners (e.g., BMS, Lilly, AstraZeneca) to successfully develop and market drugs, over which Nektar has little control[203](index=203&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=52&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section reports on any unregistered sales or repurchases of the company's equity securities during the period - There were no unregistered sales of equity securities or company repurchases of its stock in the three months ended June 30, 2019[257](index=257&type=chunk) [Defaults Upon Senior Securities](index=52&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section confirms whether the company has experienced any defaults on its senior securities - None[258](index=258&type=chunk) [Mine Safety Disclosures](index=52&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section indicates the applicability of mine safety disclosures to the company's operations - Not applicable[259](index=259&type=chunk) [Other Information](index=53&type=section&id=Item%205.%20Other%20Information) This section provides any additional material information not covered elsewhere in the report - None[260](index=260&type=chunk) [Exhibits](index=54&type=section&id=Item%206.%20Exhibits) This section lists all documents filed as exhibits, including certifications and XBRL data - The report includes required exhibits, such as officer certifications (Rule 13a-14(a), Section 1350) and Inline XBRL documents[261](index=261&type=chunk)[262](index=262&type=chunk)
Nektar Therapeutics (NKTR) Presents At EULAR 2019 - Slideshow
2019-06-14 20:04
| --- | --- | --- | --- | |-------|-------|--------------|------------------------------------| | | | | | | | | | | | | | | | | | | 2019 EULAR | European Congress of Rheumatology | | | | Analyst Call | June 13, 2019 | | | | | | This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual r ...
Nektar(NKTR) - 2019 Q1 - Earnings Call Transcript
2019-05-09 04:31
Nektar Therapeutics (NASDAQ:NKTR) Q1 2019 Earnings Conference Call May 8, 2019 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President of Investor Relations Howard Robin - President and Chief Executive Officer Gil Labrucherie - Senior Vice President and Chief Financial Officer Steven Doberstein - Head of R&D Jonathan Zalevsky - Chief Scientific Officer Mary Tagliaferri - Chief Medical Officer Conference Call Participants Chris Shibutani - Cowen Jessica Fye - JP Morgan George Farmer - BMO C ...
Nektar(NKTR) - 2019 Q1 - Quarterly Report
2019-05-08 23:42
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware 94-3134940 (State or other jurisdiction of incorpora ...
Nektar(NKTR) - 2018 Q4 - Annual Report
2019-03-01 11:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the fiscal year ended December 31, 2018 or Form 10-K ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...
Nektar(NKTR) - 2018 Q4 - Earnings Call Transcript
2019-03-01 03:57
Nektar Therapeutics (NASDAQ:NKTR) Q4 2018 Earnings Conference Call February 28, 2019 5:00 PM ET Company Participants Jennifer Ruddock ??? Head-Investor Relations Howard Robin ??? President and Chief Executive Officer Mary Tagliaferri ??? Chief Medical Officer Gil Labrucherie ??? Chief Financial Officer Jonathan Zalevsky ??? Chief Scientific Officer Conference Call Participants Jessica Fye ??? JPMorgan Chris Shibutani ??? Cowen Paul Choi ??? Goldman Sachs George Farmer ??? BMO Capital Markets Alexander Dunca ...
Nektar Therapeutics (NKTR) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
2019-01-10 10:59
| --- | --- | |-------|-----------------------------------| | | | | | 37th Annual | | | J.P. Morgan Healthcare Conference | | | Howard Robin | | | President & CEO | | | January 8, 2019 | 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and thes ...